$LENZ
LENZ Therapeutics, Inc. Stock $lenz

$lenz Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000181577624000071 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$6.494M
YoY Change		-42.48%
% of Gross Profit
Research & Development		$6.451M
YoY Change		170.6%
% of Gross Profit
Depreciation & Amortization		$10.00K
YoY Change		-98.75%
% of Gross Profit
Operating Expenses		$12.95M
YoY Change		-48.28%
Operating Profit		-$12.95M
YoY Change		-48.28%
Interest Expense		$2.736M
YoY Change		-7.57%
% of Operating Profit
Other Income/Expense, Net		$2.730M
YoY Change		7.4%
Pretax Income		-$10.22M
YoY Change		-54.58%
Income Tax
% Of Pretax Income
Net Earnings		-$10.22M
YoY Change		-54.57%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.38
Diluted Earnings Per Share		-$0.38
COMMON SHARES
Basic Shares Outstanding	27.50M shares	27.50M shares
Diluted Shares Outstanding		27.17M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$217.1M
YoY Change		-7.21%
Cash & Equivalents		$41.05M
Short-Term Investments		$176.1M
Other Short-Term Assets		$3.597M
YoY Change		-25.06%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$220.7M
YoY Change		-7.57%
LONG-TERM ASSETS
Property, Plant & Equipment		$372.0K
YoY Change		-97.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$1.398M
YoY Change
Total Long-Term Assets		$3.303M
YoY Change		-87.97%
TOTAL ASSETS
Total Short-Term Assets		$220.7M
Total Long-Term Assets		$3.303M
Total Assets		$224.0M
YoY Change		-15.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.762M
YoY Change		-26.41%
Accrued Expenses		$4.948M
YoY Change		-43.77%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$7.710M
YoY Change		-38.5%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$64.00K
YoY Change		-99.87%
Total Long-Term Liabilities		$64.00K
YoY Change		-99.87%
TOTAL LIABILITIES
Total Short-Term Liabilities		$7.710M
Total Long-Term Liabilities		$64.00K
Total Liabilities		$8.727M
YoY Change		-85.97%
SHAREHOLDERS EQUITY
Retained Earnings		-$132.4M
YoY Change		-61.52%
Common Stock		$0.00
YoY Change		-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$215.3M
YoY Change
Total Liabilities & Shareholders Equity		$224.0M
YoY Change		-15.86%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$10.22M
YoY Change		-54.57%
Depreciation, Depletion And Amortization		$10.00K
YoY Change		-98.75%
Cash From Operating Activities		-$10.58M
YoY Change		12.56%
INVESTING ACTIVITIES
Capital Expenditures		$186.0K
YoY Change		-96.14%
Acquisitions
YoY Change
Other Investing Activities		-$62.04M
YoY Change		-190.32%
Cash From Investing Activities		-$62.23M
YoY Change		-197.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		29.82M
YoY Change
NET CHANGE
Cash From Operating Activities		-10.58M
Cash From Investing Activities		-62.23M
Cash From Financing Activities		29.82M
Net Change In Cash		-42.99M
YoY Change		-178.92%
FREE CASH FLOW
Cash From Operating Activities		-$10.58M
Capital Expenditures		$186.0K
Free Cash Flow		-$10.77M
YoY Change		-24.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity File Number EntityFileNumber	001-40532
	dei	Entity Central Index Key EntityCentralIndexKey	0001815776
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-4867570
	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 Lomas Santa Fe Dr., Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Solana Beach
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92075
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	925-7000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
	dei	Trading Symbol TradingSymbol	LENZ
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27500892	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41046000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35140000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	176061000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	30654000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3483000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1450000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	114000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	220704000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	67244000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	372000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1533000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	318000	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	0	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	2739000	usd
CY2024Q3	us-gaap	Assets Assets	224007000	usd
CY2023Q4	us-gaap	Assets Assets	70376000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2762000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	64000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	121000	usd
CY2024Q3	lenz	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	0	usd
CY2023Q4	lenz	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	871000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	8727000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	19698000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	143390000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16017929	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27500401	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2004783	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27480634	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1969360	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	347119000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2517000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-132362000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95245000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	523000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	215280000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-92712000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	224007000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70376000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6451000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17004000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1956282	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-23.66
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	LENZ THERAPEUTICS, INC.
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1398000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5711000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4948000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12803000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7710000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18514000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	953000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	192000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23933000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39968000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6494000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2861000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19452000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7472000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	12945000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	19865000	usd
	us-gaap	Operating Expenses OperatingExpenses	43385000	usd
	us-gaap	Operating Expenses OperatingExpenses	47440000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12945000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19865000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43385000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-47440000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-101000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	281000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-174000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2736000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1086000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5987000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1338000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2730000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	985000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6268000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1164000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-10215000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-18880000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37117000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-46276000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	585000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	517000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9630000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18871000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36600000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46281000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.62
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.66
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27172330	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27172330	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1961822	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1961822	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19195399	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19195399	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1956282	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-92712000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	143390000	usd
CY2024Q1	lenz	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	116145000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	49840000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1918000	usd
CY2024Q1	lenz	Adjustments To Additional Paid In Capital Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalRecapitalizationTransactionCosts	5146000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7000	usd
CY2024Q1	lenz	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	430000	usd
CY2024Q1	lenz	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	10000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	947000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-16648000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	198167000	usd
CY2024Q2	lenz	Adjustments To Additional Paid In Capital Reverse Recapitalization Accounting And Issuance Of Common Stock AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationAccountingAndIssuanceOfCommonStock	31000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3413000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-61000	usd
CY2024Q2	lenz	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	28000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1597000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-10254000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	192921000	usd
CY2024Q3	lenz	Adjustments To Additional Paid In Capital Reverse Recapitalization Accounting And Issuance Of Common Stock AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationAccountingAndIssuanceOfCommonStock	29000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29693000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	57000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	585000	usd
CY2024Q3	lenz	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	19000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2191000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-10215000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	215280000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-24169000	usd
CY2023Q1	lenz	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	19000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	142000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-12670000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-36678000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14000	usd
CY2023Q2	lenz	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	19000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	189000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-14726000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-51210000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000	usd
CY2023Q3	lenz	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	19000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	494000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-18880000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-69568000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37117000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-46276000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2593000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	546000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1047000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	146000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4735000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	825000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	684000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-485000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5599000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-232000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8758000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6167000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1377000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-10000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50313000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39410000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	195297000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	46264000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	53000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	319000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-142616000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44794000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	82976000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	568000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79598000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	lenz	Proceeds From Merger Cash Cash Equivalents And Restricted Cash Financing Activities ProceedsFromMergerCashCashEquivalentsAndRestrictedCashFinancingActivities	117824000	usd
	lenz	Proceeds From Merger Cash Cash Equivalents And Restricted Cash Financing Activities ProceedsFromMergerCashCashEquivalentsAndRestrictedCashFinancingActivities	0	usd
	lenz	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	2373000	usd
	lenz	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3900000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	203000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	198949000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	82611000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6020000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1593000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35140000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44441000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41160000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42848000	usd
	lenz	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	1918000	usd
	lenz	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	0	usd
	lenz	Prepaid Expenses And Other Current Assets Acquired Through Reverse Recapitalization PrepaidExpensesAndOtherCurrentAssetsAcquiredThroughReverseRecapitalization	1313000	usd
	lenz	Prepaid Expenses And Other Current Assets Acquired Through Reverse Recapitalization PrepaidExpensesAndOtherCurrentAssetsAcquiredThroughReverseRecapitalization	0	usd
	lenz	Accounts Payable And Accrued Liabilities Acquired Through Reverse Recapitalization AccountsPayableAndAccruedLiabilitiesAcquiredThroughReverseRecapitalization	2950000	usd
	lenz	Accounts Payable And Accrued Liabilities Acquired Through Reverse Recapitalization AccountsPayableAndAccruedLiabilitiesAcquiredThroughReverseRecapitalization	0	usd
	lenz	Common Stock Issuance Costs Included In Accounts Payable And Accrued Expenses CommonStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	81000	usd
	lenz	Common Stock Issuance Costs Included In Accounts Payable And Accrued Expenses CommonStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	0	usd
	lenz	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Merger RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityMerger	146000	usd
	lenz	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Merger RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityMerger	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1205000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	190000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	lenz	Deferred Offering Costs Including In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludingInAccountsPayableAndAccruedExpenses	0	usd
	lenz	Deferred Offering Costs Including In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludingInAccountsPayableAndAccruedExpenses	1298000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-132400000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	217200000	usd
CY2024Q1	lenz	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.2022
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Estimates used in preparing the accompanying financial statements include, but are not limited to, estimates related to the research and development accruals, preferred stock warrants liability, and share-based compensation. Although actual results could differ from those estimates, management does not believe that such differences would be material.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></div>
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	2700000	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	0	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	lenz	Number Of Board Of Director Members Former Stockholder NumberOfBoardOfDirectorMembersFormerStockholder	5	member
CY2024Q1	lenz	Number Of Board Of Directors Combined Company NumberOfBoardOfDirectorsCombinedCompany	7	member
CY2024Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8670653	shares
CY2024Q1	lenz	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.2022
CY2024Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	15409102	shares
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	53500000	usd
CY2024Q1	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.56
CY2024Q1	lenz	Cash And Cash Equivalents Acquired Through Reverse Recapitalization CashAndCashEquivalentsAcquiredThroughReverseRecapitalization	112600000	usd
CY2024Q1	lenz	Assets Acquired Through Reverse Recapitalization AssetsAcquiredThroughReverseRecapitalization	1500000	usd
CY2024Q1	lenz	Payables And Accruals Acquired Through Reverse Recapitalization PayablesAndAccrualsAcquiredThroughReverseRecapitalization	3200000	usd
CY2024Q1	lenz	Adjustments To Additional Paid In Capital Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalRecapitalizationTransactionCosts	5200000	usd
	lenz	Reverse Recapitalization Acceleration Of Stock Awards Expense ReverseRecapitalizationAccelerationOfStockAwardsExpense	300000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	33865000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	176061000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	7962000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	30654000	usd
CY2023Q4	lenz	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	871000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	871000	usd
CY2024Q3	lenz	Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost	209402000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	541000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	usd
CY2024Q3	lenz	Cash Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsAndAvailableForSaleDebtSecurities	209926000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	30646000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	30654000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	165612000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	166073000	usd
CY2024Q3	lenz	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date Rolling After One Through Five Years Amortized Cost DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingAfterOneThroughFiveYearsAmortizedCost	9926000	usd
CY2024Q3	lenz	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date Rolling After One Year Fair Value DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingAfterOneYearFairValue	9988000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	175538000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	176061000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	8	position
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	11700000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	8	position
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	0	usd
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	0	usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1300000	usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	0	usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount	0	usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount	0	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2190000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1998000	usd
CY2024Q3	lenz	Accrued Sales General And Administrative Expense Current AccruedSalesGeneralAndAdministrativeExpenseCurrent	1146000	usd
CY2023Q4	lenz	Accrued Sales General And Administrative Expense Current AccruedSalesGeneralAndAdministrativeExpenseCurrent	376000	usd
CY2024Q3	lenz	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	982000	usd
CY2023Q4	lenz	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	10289000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	625000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	137000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4948000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12803000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y9M18D
CY2024Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.077
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	151000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	577000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	511000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	361000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1600000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	168000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1432000	usd
	lenz	Number Of Demand Letters Received NumberOfDemandLettersReceived	12	demand_letter
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	53761506	shares
CY2024Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	53761506	shares
CY2024Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2024Q1	lenz	Stock Issued During Period Shares Reverse Recapitalization StockIssuedDuringPeriodSharesReverseRecapitalization	8320485	shares
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1578947	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	19.00
CY2024Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	30000000.0	usd
	lenz	Common Stock Voting Rights Votes Per Share CommonStockVotingRightsVotesPerShare	1	vote
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4980809	shares
CY2024Q1	lenz	Class Of Warrant Or Right Preferred Stock Warrants Conversion To Common Stock Warrants ClassOfWarrantOrRightPreferredStockWarrantsConversionToCommonStockWarrants	164676	shares
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1900000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2191000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	494000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4735000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	825000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3099592	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13404320	shares
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001815776-24-000071-index-headers.html	Edgar Link	pending
0001815776-24-000071-index.html	Edgar Link	pending
0001815776-24-000071.txt	Edgar Link	pending
0001815776-24-000071-xbrl.zip	Edgar Link	pending
exhibit311q324.htm	Edgar Link	pending
exhibit312q324.htm	Edgar Link	pending
exhibit321q324.htm	Edgar Link	pending
exhibit322q324.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lenz-20240930.htm	Edgar Link	pending
lenz-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
lenz-20240930_cal.xml	Edgar Link	unprocessable
lenz-20240930_def.xml	Edgar Link	unprocessable
lenz-20240930_lab.xml	Edgar Link	unprocessable
lenz-20240930_pre.xml	Edgar Link	unprocessable
lenz-20240930_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LENZ
LENZ Therapeutics, Inc. Stock $lenz

2024 Q4 Form 10-Q Financial Statement

#000181577624000071 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LENZ LENZ Therapeutics, Inc. Stock $lenz

2024 Q4 Form 10-Q Financial Statement

#000181577624000071 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LENZ
LENZ Therapeutics, Inc. Stock $lenz